Chordate Medical SEK 41.8m Rights Issue | Q4 2023

Transaction Information

Rights issue

SEK 41,8m

2024

Financial Adviser

About Chordate Medical

Chordate Medical Holding is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and the Gulf region.

Press release

The case:

Chordates treatment method, Ozilia® Migraine, for chronic migraine and chronic rhinitis, is a simple and cost-effective, nonpharmaceutical, medical device treatment.

Kinetic Oscillation Stimulation (K.O.S) is the basis for the Ozilia® Migraine treatment system that was CE-marked in May 2021.

Results from the pivotal, randomized, placebo controlled, study PM007 was recently presented in Europe and the US demonstrated significant reduction in headache days and days with migraine –leading to increased interest in the treatment system.

Active sales aim at attaining penetration in several focus markets in Europe and Middle East, on the back of impressive study results.

Acquisition driven exit-focus – achieving commercial proof of concept in the pursuance of attracting favorable acquisition offer.

Website: https://www.chordate.com/en/

Chordate Medical SEK 41.8m Rights Issue | Q4 2023

Announced transactions

Bricknode Holding

Magle Group

Alligator Bioscience

Magle Group

Agtira

Q-linea

Ziccum

Gaming Corps

Magle Chemoswed

Immunovia

ExpreS2ion Biotech Holding

Scandion Oncology